454 related articles for article (PubMed ID: 29477390)
21. Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force.
Crown W; Buyukkaramikli N; Sir MY; Thokala P; Morton A; Marshall DA; Tosh JC; Ijzerman MJ; Padula WV; Pasupathy KS
Value Health; 2018 Sep; 21(9):1019-1028. PubMed ID: 30224103
[TBL] [Abstract][Full Text] [Related]
22. The History and Future of the "ISPOR Value Flower": Addressing Limitations of Conventional Cost-Effectiveness Analysis.
Neumann PJ; Garrison LP; Willke RJ
Value Health; 2022 Apr; 25(4):558-565. PubMed ID: 35279370
[TBL] [Abstract][Full Text] [Related]
23. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
[TBL] [Abstract][Full Text] [Related]
24. Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report.
Brazier J; Ara R; Azzabi I; Busschbach J; Chevrou-Séverac H; Crawford B; Cruz L; Karnon J; Lloyd A; Paisley S; Pickard AS
Value Health; 2019 Mar; 22(3):267-275. PubMed ID: 30832964
[TBL] [Abstract][Full Text] [Related]
25. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
[TBL] [Abstract][Full Text] [Related]
26. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
27. Toward Relevant and Credible Cost-Effectiveness Analyses for Value Assessment in the Decentralized U.S. Health Care System.
Jansen JP; Incerti D; Curtis JR
J Manag Care Spec Pharm; 2019 May; 25(5):518-521. PubMed ID: 31039069
[TBL] [Abstract][Full Text] [Related]
28. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III.
Mansley EC; Carroll NV; Chen KS; Shah ND; Piech CT; Hay JW; Smeeding J
Value Health; 2010; 13(1):14-7. PubMed ID: 19883404
[TBL] [Abstract][Full Text] [Related]
29. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
Siebert U; Rochau U; Claxton K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
[TBL] [Abstract][Full Text] [Related]
30. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
[TBL] [Abstract][Full Text] [Related]
31. The Impact of Decision Makers' Constraints on the Outcome of Value of Information Analysis.
Koffijberg H; Knies S; Janssen MP
Value Health; 2018 Feb; 21(2):203-209. PubMed ID: 29477402
[TBL] [Abstract][Full Text] [Related]
32. The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value.
Pearson SD
Value Health; 2018 Mar; 21(3):258-265. PubMed ID: 29566831
[TBL] [Abstract][Full Text] [Related]
33. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
[TBL] [Abstract][Full Text] [Related]
34. A Health Economics Approach to US Value Frameworks: Serving the Needs of Decision Making.
Norman R; Chalkidou K; Culyer AJ
Value Health; 2018 Feb; 21(2):117-118. PubMed ID: 29477387
[No Abstract] [Full Text] [Related]
35. The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.
Kaltenthaler E; Carroll C; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
Health Technol Assess; 2016 Apr; 20(26):1-48. PubMed ID: 27049841
[TBL] [Abstract][Full Text] [Related]
36. Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold.
Garrison LP; Jackson T; Paul D; Kenston M
J Manag Care Spec Pharm; 2019 Jul; 25(7):793-799. PubMed ID: 30784347
[TBL] [Abstract][Full Text] [Related]
37. Improving the usefulness of budget impact analyses: a U.S. payer perspective.
Watkins JB; Danielson D
Value Health; 2014; 17(1):3-4. PubMed ID: 24438711
[No Abstract] [Full Text] [Related]
38. Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V.
Mycka JM; Dellamano R; Kolassa EM; Wonder M; Ghosh S; Hay JW; Smeeding J
Value Health; 2010; 13(1):25-7. PubMed ID: 19883402
[TBL] [Abstract][Full Text] [Related]
39. Spanish recommendations on economic evaluation of health technologies.
López-Bastida J; Oliva J; Antoñanzas F; García-Altés A; Gisbert R; Mar J; Puig-Junoy J
Eur J Health Econ; 2010 Oct; 11(5):513-20. PubMed ID: 20405159
[TBL] [Abstract][Full Text] [Related]
40. The Value of Medicines: A Crucial but Vague Concept.
Antoñanzas F; Terkola R; Postma M
Pharmacoeconomics; 2016 Dec; 34(12):1227-1239. PubMed ID: 27444306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
